Literature DB >> 2011304

Occurrence of AIDS in New Zealand: the first seven years. MRC AIDS Epidemiology Group.

R V Carlson1, D C Skegg, C Paul, G F Spears.   

Abstract

The 179 people in New Zealand with AIDS diagnosed up to the end of 1989 and notified by 30 June 1990 are reviewed. Retrospective data collection provided the first available information on date of diagnosis, ethnic affiliation, district of usual residence, and survival. Of the 179 people with AIDS, 173 were male. AIDS occurred most commonly between the ages of 30 and 50, but there were two children under 10. The standardised cumulative incidence rates (per 100,000) in the European, Maori, and Pacific Island populations were 5.3, 4.5, and 5.5, respectively. The majority affected (154) were men who had had sexual contact with men. Three of five intravenous drug users also reported such contact. Smaller numbers were presumed to have been infected through heterosexual contact (7), treatment of haemophilia (3), blood transfusions (2), or perinatally (1). In seven cases the mode of transmission was unknown. The proportion of people who had been living overseas when first diagnosed was initially high but declined, so that 134 were known to have been diagnosed in New Zealand. Of these, 107 lived in Auckland or Wellington. Survival analysis using the Kaplan-Meier method showed that the median time from diagnosis to death was 58 weeks.

Entities:  

Mesh:

Year:  1991        PMID: 2011304

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  2 in total

Review 1.  Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.

Authors:  H D Langtry; K J Palmer; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

2.  HIV surveillance by testing saliva from injecting drug users: a national study in New Zealand.

Authors:  N P Dickson; F J Austin; C Paul; K J Sharples; D C Skegg
Journal:  J Epidemiol Community Health       Date:  1994-02       Impact factor: 3.710

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.